Press Releases

Press Releases

All Releases
Dec 12, 2018
NEW YORK --(BUSINESS WIRE)--Dec. 12, 2018-- Ophthotech Corporation (NASDAQ:OPHT) announced today the election of Adrienne L. Graves , Ph.D., former Chief Executive Officer of Santen Inc. , the U.S. arm of Japan’s largest ophthalmic pharmaceutical company, to its Board of Directors, effective
Nov 12, 2018
NEW YORK --(BUSINESS WIRE)--Nov. 12, 2018-- Ophthotech Corporation (NASDAQ:OPHT) today announced the results from its Phase 2a safety trial of Zimura ® (avacincaptad pegol), the Company’s complement factor C5 inhibitor, in patients with wet age-related macular degeneration (AMD).
Oct 31, 2018
- Conference Call and Webcast to Discuss Q3 2018 Results and Two Pipeline Deals Announced Today - (Conference Call: Today, October 31, 2018 , at 8:00 a.m. ET ) NEW YORK --(BUSINESS WIRE)--Oct. 31, 2018-- Ophthotech Corporation (Nasdaq:OPHT) today announced financial and operating results for the
Oct 31, 2018
- Ophthotech Enters into Second Series of Gene Therapy Agreements with the University of Pennsylvania and the University of Florida for Exclusive Option for Novel Product Candidates to Treat Best Disease - NEW YORK --(BUSINESS WIRE)--Oct. 31, 2018-- Ophthotech Corporation (NASDAQ:OPHT) announced
Oct 31, 2018
- Ophthotech Gains HtrA1 Inhibitors to Treat Age-related Retinal Diseases - - Versant Ventures Receives Equity Position in OPHT - - Conference Call and Webcast Today , October 31, 2018 at 8:00 a.m. ET - NEW YORK --(BUSINESS WIRE)--Oct. 31, 2018-- Ophthotech Corporation (NASDAQ: OPHT) announced
Oct 23, 2018
NEW YORK --(BUSINESS WIRE)--Oct. 23, 2018-- Ophthotech Corporation (Nasdaq:OPHT) today announced that it will report its third quarter 2018 financial and operating results on Wednesday, October 31, 2018 . Following the announcement, Ophthotech’s management team will host a live conference call and
Oct 04, 2018
- Initial Top-line Zimura Geographic Atrophy Data Expected in the Fourth Quarter of 2019 - - Zimura Wet AMD Data Continues on Track for Initial Top-line Data Before the End of 2018 - NEW YORK --(BUSINESS WIRE)--Oct. 4, 2018-- Ophthotech Corporation (NASDAQ:OPHT) announced completion of patient
Oct 03, 2018
NEW YORK --(BUSINESS WIRE)--Oct. 3, 2018-- Ophthotech Corporation (Nasdaq: OPHT) announced today that Keith Westby , Chief Operating Officer, will present an overview of the Company at Chardan’s 2 nd Annual Genetic Medicines Conference , on Tuesday, October 9, 2018 at 8:30 a.m. Eastern Time .
Aug 22, 2018

- Preclinical Proof-of-Concept Results in a Large Animal Model Published Online Ahead of Print in PNAS - NEW YORK --(BUSINESS WIRE)--Aug. 22, 2018-- Ophthotech Corporation (NASDAQ: OPHT) announced today that scientists at the University of Pennsylvania ( Penn ) and University of Florida published

Aug 01, 2018

(Conference Call and Webcast Today, August 1, 2018 , at 8:00 a.m. ET ) NEW YORK --(BUSINESS WIRE)--Aug. 1, 2018-- Ophthotech Corporation (Nasdaq:OPHT) today announced financial and operating results for the second quarter ended June 30, 2018 and provided a business update.

Jul 25, 2018

NEW YORK --(BUSINESS WIRE)--Jul. 25, 2018-- Ophthotech Corporation (Nasdaq: OPHT) today announced that it will report its second quarter 2018 financial and operating results on Wednesday, August 1, 2018 . Following the announcement, Ophthotech’s management team will host a live conference call and

Jun 07, 2018

- Expands Gene Therapy Portfolio with a Novel Mutation Independent Product Candidate for Autosomal Dominant Retinitis Pigmentosa - - Phase 1/2 Clinical Trial Expected to Initiate in Early 2020 - NEW YORK --(BUSINESS WIRE)--Jun. 7, 2018-- Ophthotech Corporation (NASDAQ: OPHT) announced today that it

May 09, 2018

(Conference Call and Webcast Today, May 9, 2018 , at 8:00 a.m. ET ) NEW YORK --(BUSINESS WIRE)--May 9, 2018-- Ophthotech Corporation (Nasdaq:OPHT) today announced financial and operating results for the first quarter ended March 31, 2018 and provided a business update.

May 01, 2018

- Initial Top-line Data Expected by the End of 2018 - NEW YORK --(BUSINESS WIRE)--May 1, 2018-- Ophthotech Corporation (NASDAQ: OPHT) today announced the completion of patient enrollment in its Phase 2a clinical trial of Zimura ® (avacincaptad pegol), the Company’s complement factor C5 inhibitor,

May 01, 2018

NEW YORK --(BUSINESS WIRE)--May 1, 2018-- Ophthotech Corporation (Nasdaq:OPHT) today announced that it will report its first quarter 2018 financial and operating results on Wednesday, May 9, 2018 . Following the announcement, Ophthotech’s management team will host a live conference call and webcast

Mar 06, 2018
NEW YORK --(BUSINESS WIRE)--Mar. 6, 2018-- Ophthotech Corporation (Nasdaq: OPHT) announced today that Kourous A. Rezaei, M.D., Chief Medical Officer, will present an overview of the Company at the Cowen and Company 38th Annual Health Care Conference in Boston, MA on Tuesday, March 13, 2018 at 9:20
Feb 27, 2018
(Conference Call and Webcast Today, February 27, 2018 , at 8:00 a.m. ET ) - Ophthotech Targets Novel Gene Therapy Technology for Orphan and Age-Related Retinal Diseases - - Complement C5 Inhibitor, Zimura ® , on Track with Four Ongoing Ophthalmic Clinical Programs - NEW YORK --(BUSINESS WIRE)--Feb.
Feb 27, 2018
– Ophthotech collaborates with University of Massachusetts Medical School on novel technology for next-generation gene delivery technology and novel gene therapies for ophthalmic diseases – – Collaboration is led by Guangping Gao and Hemant Khanna at UMass Medical School’s Horae Gene Therapy Center
Feb 21, 2018
NEW YORK --(BUSINESS WIRE)--Feb. 21, 2018-- Ophthotech Corporation (Nasdaq:OPHT) today announced that it will report its fourth quarter and full year 2017 financial and operating results on Tuesday, February 27, 2018 . Following the announcement, Ophthotech’s management team will host a live
Jan 16, 2018
- One of the Largest Interventional Clinical Trials for the Treatment of STGD1, an Inherited Orphan Retinal Disease – - Zimura Is Also Being Investigated in Ongoing Clinical Trials for the Treatment of Dry and Wet Age-related Macular Degeneration (AMD) and Idiopathic Polypoidal Choroidal